The AJMC® Leukemia & Lymphoma compendium is a comprehensive resource for clinical news and expert insights for the blood cancers and their treatments.
NCCN Recommends Zanubrutinib as First-Line, Second-Line Therapy in CLL, SLL
The National Comprehensive Cancer Network (NCCN) recommended zanubrutinib, approved by the FDA for the treatment of adult patients with mantle cell lymphoma, as a first-line and second-line therapy for treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
The 6 Factors That Predict ICU Admission in Patients With Hematologic Cancers
Both clinical and physician-based factors play a role in the risk of a patient with hematologic malignancies ending up in the ICU.
Venetoclax With Decitabine Outperforms Intensive Chemotherapy in Older Patients With AML
A new study may help clear up questions about the superiority of venetoclax with hypomethylating agents in patients who are deemed to be at high risk of treatment-related mortality.
Immunological Status Affects Efficacy of Mogamulizumab in ATL, Study Finds
A new study helps explain immunological factors that appear to have an impact on the success rate of mogamulizumab in patients with adult T-cell leukemia-lymphoma (ATL).
Dr Ian Flinn: Venetoclax, BTK Inhibitor Combination May Induce Greater Remission in Patients With CLL
SEQUOIA arm D study results show better outcomes are possible for patients with 17p-deletion CLL, explained Ian Flinn, MD, PhD, director of lymphoma research at Sarah Cannon Research Institute.
Single-Agent Ibrutinib Leads to Durable Responses in Relapsed/Refractory MZL
Patients who previously were treated with rituximab saw durable responses when given single-agent ibrutinib, and the drug’s safety profile in a new study matches earlier findings.
Dr Michael Green: Neurotoxicity, Poor Molecular Response Are Top Investigative Priorities
Investigating circulating tumor DNA is a top priority for patients with diffuse large B-cell lymphoma, noted Michael R. Green, PhD, Department of Lymphoma/Myeloma, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center.
Late Effects of Therapy Plague Many Patients Who Survived AML as Youths, Young Adults
Most patients who are diagnosed with acute myeloid leukemia are in middle or old age. The relatively small number who are diagnosed earlier in life can be subject to long-term health risks due to their treatment.
Rituximab Lowers Health Care Costs in DLBCL, Japanese Study Finds
A new report finds including rituximab in first-line therapy for diffuse large B-cell lymphoma (DLBCL) results in better overall outcomes that more than offset the higher initial cost of therapy.
Meta-Analysis: Living Near Petrochemical Facilities Raises Risk of Leukemia
The risk of leukemia is higher for people living near petroleum industry complexes, according to a new analysis of 13 studies of the issue.
Myriad Strategies Being Developed to Fight Resistance in CAR T-Cell Therapy for Hematological Malignancies
Chimeric antigen receptor (CAR) T cells can be highly effective, but the durability of the therapy has been lacking in many patients with hematological malignancies. Many efforts are underway to fix this problem.
Male, White, Older Patients With Leukemia at Heightened Risk of Suicide, Study Finds
In what is believed to be the first study of its kind, investigators found patients with leukemia face a higher risk of suicide than the general public, especially if they had acute myeloid leukemia.
Patients With ALL Have High Readmission Risk Post Chemotherapy, but Hospitals Can Change That
Many patients with acute lymphoblastic leukemia (ALL) who undergo chemotherapy end up back in the hospital within 30 days. A new study points out the reasons and opportunities for prevention.
Dr Michael Green Explains the Link Between Monocyte-Like Cells, Neurotoxicity After CAR T Therapy
Immune-associated neurotoxicity in patients following chimeric antigen receptor (CAR) T-cell therapy may be due to monocyte-like cells in infusion products, explained Michael R. Green, PhD, University of Texas MD Anderson Cancer Center.
Prior Malignancy Linked to Risk of Secondary Malignancy in Follicular Lymphoma
Previous research has found a link between a prior malignancy and secondary primary malignancy risk in patients with multiple myeloma. A new study suggests a similar association in follicular lymphoma.
Case Report Suggests Nivolumab Is Effective in Burkitt Lymphoma
A 72-year-old patient with Burkitt lymphoma was successfully treated with nivolumab after standard-of-care chemotherapy failed.
Dr Michael Green Discusses Understanding Patient Response to CAR T-Cell Therapy
Chimeric antigen receptor (CAR) T-cell therapy does not always lead to a durable response, and we are trying to figure out why, noted Michael R. Green, PhD, University of Texas MD Anderson Cancer Center.
Review Lays Out the Tough Task of Discerning T-cell Prolymphocytic Leukemia
T-cell prolymphocytic leukemia is rare and shares many features with other conditions. A new review article helps explain some of the tactics physicians can use to correctly identify it.
Pembrolizumab Expanded to Treat Relapsed, Refractory cHL in Adults, Children
It is the first PD-1 inhibitor to be approved to be used as a monotherapy for the treatment of adult and pediatric patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL).
MRD Negativity Indicative of Improved OS, DFS in AML, Study Says
Based on the findings, the researchers are arguing that minimal residual disease (MRD) should be considered as a clinical trial endpoint.
Dual US, China Approval Process for Zanubrutinib Shows Regulatory Differences
The process of approving a new therapy for relapsing and/or remitting mantle cell lymphoma therapy got off to a faster start in China, but United States regulators caught up and approved the drug first.
Case Report: Ibrutinib Might Protect Against Acute Lung Injury in Patients With CLL, COVID-19
A patient with chronic lymphocytic leukemia (CLL) was continued on ibrutinib even after developing severe coronavirus disease 2019 (COVID-19). He successfully overcame the infection.
HSCT Viable for Children With Nonremission Acute Lymphoblastic Leukemia
Research into children and adolescents with nonremission acute lymphoblastic leukemia (ALL) has been sparse, but a new analysis suggests that allogeneic hematopoietic stem cell transplantation is a good fit for some patients.
TKI Leads to Superior Outcomes in ALL With an ABL-Class Fusion, Study Says
Patients with acute lymphoblastic leukemia (ALL) who have an ABL-class fusion had better outcomes than a control group when treated with tyrosine kinase inhibitors at their first relapse, according to a new study.
Novel CAR T-Cell Process Shows Promise in Relapsing/Refractory B-ALL
A new chimeric antigen receptor (CAR) T cell therapy may help curb the problem of frequent relapse in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
25% of Patients With CLL See Disease Flare When Ibrutinib Therapy Pauses
Ibrutinib can lead to side effects, causing some physicians to consider reducing the dose or temporarily halting therapy, but that risks disease flares, a new study finds.
Study Finds QOL Lags in Patients With CLL, Even Before Treatment
Patients with chronic lymphocytic leukemia (CLL) have worse health-related quality of life scores compared to healthy controls, according to a new study out of India.
Hepatitis B More Prevalent in Patients With CLL Than Those With MM
New research casts doubt on the notion that hepatitis plays a role in the development of multiple myeloma (MM), finding that the virus is actually more common in chronic lymphocytic leukemia (CLL).
Identifying the Risk of Neurotoxicity After CAR T-Cell Therapy
A significant number of patients who undergo chimeric antigen receptor (CAR) T-cell therapy will experience severe neurotoxicity. A new study could help doctors better predict which patients are at risk.
CD83 Could Be Meaningful Target Against MCL, Study Finds
Mantle cell lymphoma is considered incurable, but a new strategy could lead to better results in a subgroup of patients with the cancer.
2 Clarke Drive Cranbury, NJ 08512